Onco-Innovations Partners with Nanosoft Polymers for ONC010 Development
Onco-Innovations enters LOI with Nanosoft Polymers to develop ONC010 PNKP inhibitor for solid tumours, appoints Dave Antony as VP of corporate finance to support growth strategy.
This news matters because Onco-Innovations' progress with ONC010, a PNKP inhibitor for solid tumours, could lead to a novel cancer therapy. The appointment of Dave Antony strengthens the company's financial strategy, potentially accelerating development. For investors and patients, this signals a focused effort to bring innovative treatments to market, addressing a critical need in oncology.
